Anticoagulation Therapy for Deep Vein Thrombosis

Standard Treatment Regimen

The American College of Cardiology recommends apixaban 10 mg orally twice daily for 7 days, then 5 mg twice daily for at least 3 months, for uncomplicated DVT treatment 1, 2
Apixaban can be initiated directly without any parenteral anticoagulation for DVT treatment, with an initial phase of 10 mg orally twice daily for the first 7 days, followed by a maintenance phase of 5 mg orally twice daily starting on day 8 1, 2, 3, 4
The minimum duration of anticoagulation for provoked DVT is 3 months 1, 2
Extended therapy with apixaban 5 mg twice daily or reduced to 2.5 mg twice daily can be considered after 6 months of initial therapy, based on risk factors 1, 2, 3

For cancer-associated DVT, the American College of Cardiology prefers enoxaparin 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily for the first 6 months 1, 2, 5
In patients with severe renal impairment (CrCl <30 mL/min), enoxaparin is preferred over apixaban 6, 7
For patients with inability to take oral medications, enoxaparin 1 mg/kg every 12 hours or 1.5 mg/kg once daily can be used until oral therapy is feasible 6, 8

The American College of Cardiology recommends at least 3 months of anticoagulation for all DVT patients 1, 2, 5
For unprovoked DVT, consider indefinite anticoagulation with annual reassessment 1, 2, 9
For recurrent VTE, indefinite anticoagulation is recommended 1, 2
For active cancer, continue anticoagulation for at least 6 months, often indefinitely while cancer is active 1, 2, 5

After 6 months of standard-dose apixaban (5 mg twice daily), a reduced dose of 2.5 mg twice daily can be used for extended secondary prevention 1, 2, 3
This reduced dose maintains efficacy while potentially lowering bleeding risk 1, 2

For patients with CrCl 15-30 mL/min, apixaban can be used with caution at standard initial dosing, but consider 2.5 mg twice daily for extended therapy 9
For patients with CrCl <15 mL/min, apixaban is contraindicated; use enoxaparin with anti-Xa monitoring or unfractionated heparin 10, 7, 9

The American College of Cardiology recommends apixaban can be initiated directly without any parenteral anticoagulation for DVT treatment, unlike dabigatran and edoxaban, which require 5-10 days of parenteral lead-in therapy 11, 12

The American College of Cardiology suggests starting apixaban 10 mg orally twice daily, regardless of when the last enoxaparin dose was given, and continuing this dose for the first 7 days 11
Then, transition to 5 mg orally twice daily starting on day 8, as recommended by the American College of Cardiology 11

Apixaban was specifically designed with an initiation dose regimen that eliminates the need for parenteral bridging, distinguishing it from dabigatran and edoxaban, according to the American College of Cardiology 11, 13

The American College of Cardiology notes that no waiting period is required between the last enoxaparin dose and first apixaban dose, as the single dose of enoxaparin already given provides some anticoagulation coverage 12
For patients with severe renal impairment, the American College of Cardiology recommends continuing enoxaparin instead of apixaban, as apixaban is contraindicated with CrCl <15 mL/min 13

The American College of Cardiology advises against confusing the VTE treatment dose with the atrial fibrillation dose, as the higher initiation dose is critical for adequate anticoagulation in acute thrombosis 11
The American College of Cardiology recommends against using the reduced dose during initial treatment, as this dose is only for extended secondary prevention after completing at least 6 months of standard therapy 11

After 6 months of standard-dose therapy, the American College of Cardiology suggests considering reducing to 2.5 mg twice daily for extended secondary prevention to lower bleeding risk while maintaining efficacy 11

Administer apixaban 10 mg orally twice daily for the first 7 days without any parenteral anticoagulant lead‑in. This regimen provides immediate therapeutic anticoagulation and eliminates the need for bridging with enoxaparin or unfractionated heparin. Level I evidence (AMPLIFY RCT). 14
The AMPLIFY trial showed that the 10 mg BID loading regimen is non‑inferior to enoxaparin followed by warfarin for treatment of acute VTE and yields significantly lower major bleeding (0.6 % vs 1.8 %; p < 0.001). Level I evidence. 14

Switch to apixaban 5 mg orally twice daily beginning on day 8 and continue for a minimum total duration of 3 months in patients with provoked DVT from long‑haul travel. Level I evidence. 14

For a transient/reversible provoking factor such as long‑haul travel, anticoagulation should be discontinued after 3 months. Class I, Level A recommendation (CHEST 2021 guidelines). [15][16]
Extension of therapy beyond 3 months is not indicated unless the patient experiences a recurrent DVT. Class I, Level A. [15][16]

The age ≥ 80 years and weight ≤ 60 kg dose‑reduction criteria used for atrial‑fibrillation do not apply to apixaban when treating VTE; the standard 10 mg BID loading and 5 mg BID maintenance doses are used regardless of age or weight (unless severe renal impairment). Level I evidence. 14
For extended VTE therapy beyond 6 months, a reduced apixaban dose of 2.5 mg twice daily may be considered, but this is not applicable to a 3‑month provoked DVT regimen. Class IIa, Level B (CHEST 2021). [15][16]

Alternative	Dosing Regimen (Provoked DVT)	Key Notes
Rivaroxaban	15 mg orally twice daily with food for 21 days, then 20 mg once daily	Direct oral factor Xa inhibitor; no parenteral lead‑in required.	[14][17]
Enoxaparin	1 mg/kg subcutaneously every 12 h for 3 months (preferred if CrCl < 30 mL/min)	Low‑molecular‑weight heparin; requires dose adjustment for severe renal impairment.	[17]
Edoxaban	5‑10 days of parenteral anticoagulation, then 60 mg once daily (or 30 mg if weight < 60 kg or CrCl 30‑50 mL/min)	Direct oral factor Xa inhibitor; requires initial parenteral bridge.	[14][17]
Dabigatran	5‑10 days of parenteral anticoagulation, then 150 mg twice daily	Direct thrombin inhibitor; requires initial parenteral bridge.	[14][17]

Routine laboratory monitoring of anticoagulant effect is not required for apixaban at standard doses. Level III (expert consensus). 17
Baseline laboratory assessment should include a complete blood count with platelets, renal function, hepatic function, and PT/INR. Guideline recommendation. 17
If clinically significant bleeding is suspected, repeat hemoglobin/hematocrit testing is advised, but no regular monitoring schedule is needed. Guideline recommendation. 17